[1]
|
Lee, Y., Basith, S. and Choi, S. (2018) Recent Advances in Structure-Based Drug Design Targeting Class A G-Protein Coupled Receptors Utilizing Crystal Structures and Computational Simulations. Journal of Medicinal Chemistry, 61, 1-46.
https://doi.org/10.1021/acs.jmedchem.6b01453
|
[2]
|
Hu, G.-M., Mai, T.-L. and Chen, C.-M. (2017) Visualization of the GPCR Network: Classification and Evolution. Scientific Reports, 7, Article No. 15495.
https://doi.org/10.1038/s41598-017-15707-9
|
[3]
|
Hauser, A.S., Attwood, M.M., Rask-Andersen, M., Schioth, H.B. and Gloriam, D.E. (2017) Trends in GPCR Drug Discovery: New Agents, Targets and Indications. Nature Reviews Drug Discovery, 16, 829-842. https://doi.org/10.1038/nrd.2017.178
|
[4]
|
Lodowski, D.T. and Palczewski, K. (2009) Chemokine Receptors and Other GPCRs. Current Opinion in HIV and AIDS, 4, 88-95.
https://doi.org/10.1097/COH.0b013e3283223d8d
|
[5]
|
Blankeney, J.S., Reid, R.C., Le, G.T. and Fairlie, P. (2007) Nonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors. Chemical Reviews, 107, 2960-3041.
https://doi.org/10.1021/cr050984g
|
[6]
|
Hauser, A.S., Chavali, S., Masuho, I., Jahn, M.J., Martemyanov, K.A., Gloriam, D.E. and Babu, M.M. (2018) Pharmacogenomics of GPCR Drug Targets. Cell, 172, 41-54. https://doi.org/10.1016/j.cell.2017.11.033
|
[7]
|
Parthier, C., Reetz-Runge, S., Rudolf, R. and Stubbs, M.B. (2009) Passing the Baton in Class B GPCRs: Peptide Hormone Activation via Helix Induction. Trends in Biochemical Science, 34, 304-310. https://doi.org/10.1016/j.tibs.2009.02.004
|
[8]
|
Pasznik, P., Rutkowska, E., Niewieszerza, S., Cielecka-Piontek, J. and Latek, D. (2019) Potential Off-Target Effects of ?-Blockers on Gut Hormone Receptor: In Silico Study Including Gut Dock—A Web Service for Small Molecule Docking. PLoS ONE, 14, e0210705. https://doi.org/10.1371/journal.pone.0210705
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210705
|
[9]
|
Valadas, J.S., Bathalha, V.L., Ferreira, D.G., Gomes, R., Cohelo, J.A., Sebastiao, A.M., Diogenes, M.J. and Lopes, L.V. (2012) Neuroprotection Afforded by Adenosine 2a Receptor Blockade is Modulated by Corticotrophin Releasing Factor Receptor in Glutamate Injured Cortical Neurons. Journal of Neurochemistry, 123, 1030-1040. https://doi.org/10.1111/jnc.12050
|
[10]
|
Norden, D.M. and Godbout, J.P. (2013) Microglia of the Aged Brain: Primed to Be Activated and Resistant to Regulation. Neuropathology and Applied Neurobiology, 39, 19-34. https://doi.org/10.1111/j.1365-2990.2012.01306.x
|
[11]
|
Mittelbronn, M., Dietz, K., Schluesener, H.J. and Meyermann, R. (2001) Local Distribution of Microglia in the Normal Adult Central Nervous System Differs by Up to One Order of Magnitude. Acta Neuropathologica, 101, 249-255.
|
[12]
|
Lawson, L.J., Perry, V.H., Dri, P. and Gordon, S. (1990) Heterogeneity in the Distribution and Morphology of Microglia in the Normal Adult Mouse Brain. Neuroscience, 39, 151-170. https://doi.org/10.1016/0306-4522(90)90229-W
|
[13]
|
Herculano-Houzel, S. and Lent, R. (2005) Isotropic Fractionator: A Simple, Rapid Method for the Quantification of Total Cell and Neuron Numbers in the Brain. Journal of Neuroscience, 25, 2518-2521.
https://doi.org/10.1523/JNEUROSCI.4526-04.2005
|
[14]
|
Herculano-Houzel, S. (2009) Human Brain in Numbers: A Linearly Scaled-Up Primate Brain. Frontiers in Human Neuroscience, 3, Article 31.
https://doi.org/10.3389/neuro.09.031.2009
|
[15]
|
Azevedo, F.A.C., Carvalho, L.R.B., Grinberg, L.T., Farfel, J.M., Ferretti, R.E.L., Leite R.E.P., Filho, W.J., Lent, R. and Herculano-Houzel, S. (2009) Equal Numbers of Neuronal and Nonneuronal Cells Make the Human Brain and Isometrically Scaled-Up Primate Brain. Journal of Comparative Neurology, 513, 532-541.
https://doi.org/10.1002/cne.21974
|
[16]
|
Hughes, C.E and Nibbs, R.J. (2018) A Guide to Chemokines and Their Receptors. FEBS Journal, 285, 2944-2971. https://doi.org/10.1111/febs.14466
|
[17]
|
Nishiyori, A. Minami, M., Othani, Y., Takami, S., Yamamoto, J., Kawaguchi, N., Kume, T., Akaike, A. and Satoh, M. (1998) Localization of Fraktalkine and CX3CR mRNA in Rat Brains: Does Fraktalkine Play a Role in Signaling from Neuron to Microglia. FEBS Letters, 429, 167-172.
https://doi.org/10.1016/S0014-5793(98)00583-3
|
[18]
|
Hervieu, G.J., Cluderay, J.E., Harrison, D.C., Roberts, J.C. and Leslie, R.A. (2001) Gene Expression and Protein Distribution of the Orexin-1-Receptor in the Rat Brain and Spinal Cord. Neuroscience, 103, 777-797.
https://doi.org/10.1016/S0306-4522(01)00033-1
|
[19]
|
Mihara, Y., Dohi, K., Yofu, S., Nakamachi, T., Othaki, H., Shioda, S. and Aruga, T. (2011) Expression and Localization of Orexin-1-Receptor (OX1R) after Traumatic Brain Injury in Mice. Journal of Molecular Neuroscience, 43, 162-168.
https://doi.org/10.1007/s12031-010-9438-6
|
[20]
|
Carniglia, L., Ramirez, D., Durand, D. Saba, J., Turati, J., Caruso, C., Scimonelli, T.N. and Lasaga, M. (2017) Neuropeptides and Microglial Activation in Inflammation, Pain and Neurodegenerative Diseases. Mediators of Inflammation, 2017, Article ID: 5048616. https://doi.org/10.1155/2017/5048616
|
[21]
|
Santos-Carvalho, A., Aveleira, C.A., Elvas, F., Abrosio, A.F. and Cavadas, C. (2013) Neuropeptide Y Receptors NPY1 and NPY2 Are Present in Neurons and Glia Cells in Rat Retinal Cells and Culture. Investigative Ophthalmology & Visual Science, 54, 429-443. https://doi.org/10.1167/iovs.12-10776
|
[22]
|
Ferreira, R., Santos, T., Cortes, L., Cochaud, S., Agasse, F., Silva, A.P., Xapelli, S. and Malva, J.O. (2012) Neuropeptide Y Inhibits Interleukin-1 Beta-Induced Microglia Motility. Journal of Neurochemistry, 120, 93-105.
https://doi.org/10.1111/j.1471-4159.2011.07541.x
|
[23]
|
Kim, E.H., Ryu, D.H. and Hwang, S. (2011) The Expression of Corticotropin-Releasing Factor and Its Receptors in Spinal Cord and Dorsal Ganglion in a Rat Model of Neuropathic Pain. Anatomy & Cell Biology, 44, 60-68.
https://doi.org/10.5115/acb.2011.44.1.60
|
[24]
|
Greter, M., Lellios, I. and Croxford, A.L. (2015) Microglia versus Myeloid Cell Nomenclature during Brain Inflammation. Frontiers in Immunology, 6, Article 249.
https://doi.org/10.3389/fimmu.2015.00249
|
[25]
|
Szepesi, Z., Manouchehrian, O., Bachiller, S. and Deierborg, T. (2018) Bidirectional Microglia-Neuron Communication in Health and Disease. Frontiers in Cellular Neuroscience, 12, Article 323. https://doi.org/10.3389/fncel.2018.00323
|
[26]
|
Kettenmann, H., Hanisch, U.-K., Noda, M. and Verkhratsky, A. (2011) Physiology of Microglia. Physiological Reviews, 91, 461-553.
https://doi.org/10.1152/physrev.00011.2010
|
[27]
|
Hickmann, S.E., Kingery, N.D., Ohsumi, T.K., Borows, M.I., Wang, L.-C., Means, T.K. and El Khoury, J. (2013) The Microglial Sensome Revealed by Direct RNA Sequencing. Nature Neuroscience, 16, 1896-1905. https://doi.org/10.1038/nn.3554
|
[28]
|
Grabert, K., Michoel, T., Karavolos, M.H., Clohisey, S., Baillie, J.K., Stevens, M.P., Freeman, T.C., Summers, K.M. and McColl, B.W. (2016) Microglial Brain-Region Dependent Diversity and Selective Regional Sensitivities to Aging. Nature Neuroscience, 19, 504-516. https://doi.org/10.1038/nn.4222
|
[29]
|
Segal, B.M. and Giger, R.J. (2016) Stable Biomarker for Plastic Microglia. PNAS, 113, 3130-3132. https://doi.org/10.1073/pnas.1601669113
|
[30]
|
Sellgren, C.M., Gracias, J., Watmuff, B., Biag, J.D., Thanos, J.M., Wittredge, P.B., Worringer, K., Shaham, Y. and de Wit, H. ( 2016) Lost in Translation: CRF1 Receptor Antagonist and Addiction Treatment. Neuropsychopharmacology, 41, 2795-2797. https://doi.org/10.1038/npp.2016.94
|
[31]
|
Herclano-Houzel, S. (2011) Scaling of Brain Metabolism with a Fixed Energy Budget per Neuron: Implications for Neuronal Activity, Plasticity and Evolution. PLoS ONE, 6, e17514. https://doi.org/10.1371/journal.pone.0017514
|
[32]
|
Herculano-Houzel, S. (2014) The Glia/Neuron Ratio: How It Varies Uniformly across Brain Structures and Species and What Means for Brain Physiology and Evolution. Glia, 62, 1377-1391. https://doi.org/10.1002/glia.22683
|
[33]
|
Akhmetzyanova, E.R., Mukhamedshina, Y.O., Zhuravleva, N.M., Galieva, L.R., Kostennikov, A.A., Garanina, E.E. and Rizvanov, A.A. (2018) Transplantation of Microglia in the Area of Spinal Cord Injury in an Acute Period Increases Tissue Sparing, But Not Functional Recovery. Frontiers in Cellular Neuroscience, 12, 507.
https://doi.org/10.3389/fncel.2018.00507
|
[34]
|
Green, L.A., Nebiolo, J.C. and Smith, C.J. (2019) Microglia Exit the CNS in Spinal Root Avulsion. PLoS Biology, 17, e3000159.
https://doi.org/10.1371/journal.pbio.3000159
|
[35]
|
Tronel, C., Largeau, B., Ribeiro, M.J.S., Guilloteau, D., Dupont, A.-C. and Arlicot, N. (2017) Molecular Target for PET Imaging of Activated Microglia: The Current Situation and Future Expectations. International Journal of Molecular Sciences, 18, 802. https://doi.org/10.3390/ijms18040802
|
[36]
|
Ozen, I., Deierborg, T., Miharada, K., Padel, T. and Englund, E. (2014) Brain Pericytes Aquire a Microglial Phenotype after Stroke. Acta Neuropathologica, 128, 381-396. https://doi.org/10.1007/s00401-014-1295-x
|
[37]
|
Sperlagh, B. and Illes, P. (2007) Purinergic Modulation of Microglial Cell Activation. Purinergic Signalling, 3, 117-127. https://doi.org/10.1007/s11302-006-9043-x
|
[38]
|
Geloso, M.C., Corvino, V., Marchese, E., Serrano, R., Michetti, F. and D’Ambrosi, N. (2017) The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches. Frontiers in Aging Neuroscience, 9, Article 242.
https://doi.org/10.3389/fnagi.2017.00242
|
[39]
|
Sheridan, G.K. and Murphy, K.J. (2013) Neuron-Glia Cross Talk in Health and Disease: Fractalkine and CX3CR1 Central Stage. Open Biology, 3, Article ID: 130181.
https://doi.org/10.1098/rsob.130181
|
[40]
|
Pandy-Szekeresz, G., Munk, C., Tsonkov, T.M., Mordalski, S., Harpso, K., Hauser, A.S., Bojarski, A.J. and Gloriam, D.E. (2018) GPCRdb in 2018: Adding GPCR Structure Models and Ligands. Nucleic Acid Research, 46, D440-D446.
https://doi.org/10.1093/nar/gkx1109
|
[41]
|
Munk, C., Isberg, V., Mordalski, S., Harpsoe, K., Rataj, K., Hauser, A.S., Kolb, P., Bojarski, A.J., Vriend, G. and Gloriam, D.E. (2016) The GPCRdb: G-Protein Coupled Receptor Database—An Introduction. British Journal of Pharmacology, 173, 2195-2207. https://doi.org/10.1111/bph.13509
|
[42]
|
Karlstrom, S., Nordvall, G., Sohn, D., Hettman, A., Turek, D., Ahlin, K., Kers, A., Claesson, M., Slivo, C., Lo-Alfredsson, Y., Petersson, C., Bessidskaia, G., Svensson, P.H., Rein, T., Jerning, E., Malmber, A., Algen, C., Ray, C., Vares, L., Ivanov, V. and Johansson, R. (2013) Substituted 7-Amino-5-Thio-Thiazolo [4,5-d]Pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX3CR1). Journal of Medicinal Chemistry, 56, 3177-3190. https://doi.org/10.1021/jm3012273
|
[43]
|
Cederblad, L., Rosengreen, B., Ryberg, E. and Hermansson, N.-O. (2016) AZD8797 Is an Allosteric Non-Competitive Modulator of the Human CX3CR1 Receptor. Biochemical Journal, 473, 641-647. https://doi.org/10.1042/BJ20150520
|
[44]
|
Basile, A. and Skolnick, P. (1986) Subcellular Localization of “Peripheral-Type” Binding Sites for Benzodiazepines in Rat Brain. Journal of Neurochemistry, 46, 305-308. https://doi.org/10.1111/j.1471-4159.1986.tb12965.x
|
[45]
|
Stowell, R.D., Wong, E.L., Batchelor, H.N., Mendes, M.S., Lamantia, C.E., Whitelaw, B.S. and Mendes, A.K. (2017) Cerebellar Microglia Are Dynamically Unique and Survey Purkinje Neurons in Vivo. Developmental Neurobiology, 78, 627-644.
https://doi.org/10.1002/dneu.22572
|
[46]
|
Bartanusz, V., Jezova, D., Alajajian, B. and Digicaylioglu, M. (2011) The Blood Spinal Cord Barrier: Morphology and Clinical Implications. Annals of Neurology, 70, 194-206. https://doi.org/10.1002/ana.22421
|
[47]
|
Lorenzen, E., Dodig-Crnkovic, T., Kotliar, I.B., Pin, E., Ceraudo, E., Vaughan, O.D., Uhlen, M., Huber, T., Schwenk, J.M. and Sakmar, T.P. (2019) Multiplexed Analysis of the Secretin-Like GPCR-RAMP Interactom. https://doi.org/10.1101/597690
|
[48]
|
Wu, F., Song, G., De Graaf, C. and Stevens, R.C. (2017) Structure and Function of Peptide-Binding G-Protein Coupled Receptors. Journal of Molecular Biology, 420, 2726-2745. https://doi.org/10.1016/j.jmb.2017.06.022
|
[49]
|
Mease, R., Yang, X., Foss, C. and Pomper, M. (2015) Radiosynthesis and Initial in Vivo Evaluation of 2-[18F]FBTTP, a Radiotracer Targeting CX3CR1. Journal of Nuclear Medicine, 56, 356.
|
[50]
|
Hostetler, E.D., Sanabria-Bohorquez, S., Fan, H., Zeng, Z., Gantert, L., Williams, M., Miller, P., O’Malley, S., Kameda, M., Ando, M., Sato, N., Ozaki, S., Tokita, S., Otha, H., Williams, D., Sur, C., Cook, J.J., Burns, H.D. and Hargreaves, R. (2011) Synthesis, Characterization, and Monkey Positron Emission Tomography (PET) Studies of [18F]Y1-973, a PET Tracer for the Neuropeptide YY1 Receptor. Neuroimage, 54, 2635-2642. https://doi.org/10.1016/j.neuroimage.2010.11.014
|
[51]
|
Poniatowski, L.A., Woidasiewicz, P., Krawzyk, M., Sziukiewicz, D., Gasik, R., Kubaszewski, L. and Kurkowska-Jastrzebska, I. (2017) Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents. Molecular Neurobiology, 54, 2167-2188. https://doi.org/10.1007/s12035-016-9787-4
|
[52]
|
Freria, C.M., Hall, J.C.E., Wei, P., Guan, Z. M.C., Tigue, D.M. and Popovich, P.G. (2017) Deletion of the Fractalkine Receptor CX3CR Improves Endogenous Repair, Axon Sprouting, and Synaptogenesis after Spinal Cord Injury in Mice. Journal Neuroscience, 37, 3568-3587. https://doi.org/10.1523/JNEUROSCI.2841-16.2017
|
[53]
|
Bellver-Landete, V., Brethau, F., Mailhot, B., Vallier, N., Lessard, M., Jaselle, M.-E., Vernoux, M., Tremblay, M.-E., Fuehrmann, T., Shoichet, M.S. and Lacroix, S. (2019) Microglia Are an Essential Component of the Neuroprotective Scar That Forms after Spinal Cord Injury. Nature Communications, 10, 518.
https://doi.org/10.1038/s41467-019-08446-0
|
[54]
|
Statnick, M.A., Schober, D.A., Mayne, N.G., Burnett, J.P. and Gehlert, D.R. (1997) Analysis of NPY Receptor Subtypes in the Human Frontal Cortex Reveals Abundant Y1 mRNA and Binding Sites. Peptides, 18, 137-143.
https://doi.org/10.1016/S0196-9781(96)00246-X
|
[55]
|
Schober, D.A., Gackenheimer, S.L., Heiman, M.L. and Gehlert, D.R. (2000) Pharmacological Characterization of 125I-1229U91 Binding to Y1 and Y4 Neuropeptide Y/Peptide YY Receptors. Journal of Pharmacology and Experimental Therapeutics, 293, 275-280.
|
[56]
|
Monti, J.M., Spence, D.W., Butoo, K. and Pandi-Perumal, S.R. (2017) Zolpidem’s Use for Insomnia. Asian Journal of Psychiatry, 25, 79-90.
https://doi.org/10.1016/j.ajp.2016.10.006
|
[57]
|
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Groselj, L.D., Ellis, J.G., Espie, C.A., Garcia-Borreguero, D., Gjerstad, M., Goncalves, M., Hertenstein, E., Jansson-Fromark, M., Jennum, P.J., Leger, D., Nissen, C., Parrino, L., Paunio, T., Pevernagie, D., Verbraecken, J., Weeb, H.G., Wichniak, A., Zavalko, I., Arnadottir, E.S., Deleanu, O.-C., Strazisar, B., Zoetmulder, M. and Spiegelhalder, K. (2017) European Guideline for the Diagnosis and Treatment of Insomnia. Journal of Sleep Research, 26, 675-700. https://doi.org/10.1111/jsr.12594
|
[58]
|
Sullivan, G.M, Parsey, R.V., Kumar, J.S.D., Arango, V., Kassir, S.A., Huang, Y.-Y., Simpson, N.R., van Heertum, R.L. and Mann, J.J. (2007) PET Imaging of CRF1 with [11C]R121920 and DMP696: Is the Target of Sufficient Density? Nuclear Medicine and Biology, 34, 353-361. https://doi.org/10.1016/j.nucmedbio.2007.01.012
|
[59]
|
Hollenstein, A., Kean, J., Bortolato, A., Cheng, R.K.Y., Doré, A.S., Jazayeri, A., Cooke, R.M., Weir, M. and Marshall, F.H. (2013) Structure of Class B GPCR Corticotrophin Releasing Factor 1 Receptor. Nature, 499, 438-445.
https://doi.org/10.1038/nature12357
|
[60]
|
Bai, Q., Shi, D., Zhang, Y., Liu, H. and Yao, X. (2014) Exploration of the Antagonist CP376395 Escape Pathway of Corticotrophin Releasing Factor1 by Random Acceleration by Molecular Dynamics Simulation. Molecular Biosystems, 10, 1958.
https://doi.org/10.1039/c4mb00037d
|
[61]
|
Doré, A.S., Bortolato, A., Hollenstein, K., Cheng, R.K.Y., Read, R.J. and Marshall, F.H. (2017) Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structure. Current Molecular Pharmacology, 10, 334-344.
https://doi.org/10.2174/1874467210666170110114727
|
[62]
|
Cavasotto, C.N. and Palomba, D. (2015) Expanding the Horizon of G Protein-Coupled Receptor Structure-Based Ligand Discovery and Optimization Using Homology Models. Chemical Communications, 51, 13576-13594.
https://doi.org/10.1039/C5CC05050B
|
[63]
|
Burkert, K., Zellman, T., Meier, R., Kaiser, A., Stichel, J., Meiler, J., Mittapalli, G.K., Roberts, E. and Beck-Sickinger, A.G. (2017) A Deep Hydrophobic Binding Cavity Is the Main Interaction for Different Y2R Antagonist. ChemMedChem, 12, 75-85.
https://doi.org/10.1002/cmdc.201600433
|
[64]
|
Kim, H., Choi, B., Lim, H., Min, H., Oh, J.H., Choi, S., Cho, J.G., Park, J.-S. and Lee, S.J. (2017) Polyamidoamine Dendrimer-Conjugated Triamcinolone Acetonide Attenuates Nerve Injury-Induced Spinal Cord Microglia Activation and Molecular Allodynia. Molecular Pain, 13, 1-11. https://doi.org/10.1177/1744806917697006
|
[65]
|
Weiss, S., Keller, M., Bernhardt, G., Buschauer, A. and Konig, B. (2010) NG-Acyl- Argininamides as NPY Y1 Receptor Antagonists: Influence of Structurally Diverse Acyl Substituents on Stability and Affinity. Bioorganic & Medicinal Chemistry, 18, 6292-6304. https://doi.org/10.1016/j.bmc.2010.07.028
|
[66]
|
Keller, M., Schindler, L., Bernhardt, G. and Buschauer, A. (2015) Toward Labeled Argininamide-Type NPYY1 Receptor Antagonists: Identification of a Favorable Propionylation Site in BIBO3304. Arch. Pharm. Chemistry in Life Sciences, 348, 390-398. https://doi.org/10.1002/ardp.201400427
|
[67]
|
Keller, M., Maschauer, S., Brennauer, A., Tripal, P., Koglin, N., Dittrich, R., Bernhardt, G., Kuwert, T., Wester, H.-J., Buschauer, A. and Prante, O. (2017) Prototypic 18F-Labeled Argininamide-Type Neuropeptide Y Y1 R Antagonists as Tracers for PET Imaging of Mammary Carcinoma. ACS Medicinal Chemistry Letters, 8, 304-309. https://doi.org/10.1021/acsmedchemlett.6b00467
|
[68]
|
Lipinski, C.A. (2000) Drug-Like Properties and the Causes of Poor Solubility and Poor Permeability. Journal of Pharmacological and Toxicological Methods, 44, 235-249. https://doi.org/10.1016/S1056-8719(00)00107-6
|
[69]
|
Kawamura, K., Mori, W., Fujinaga, M., Yamasaki, T., Zhang, Y., Wakizaka, H., Hatori, A., Xie, L., Kumata, K., Okhubo, T., Kurihara, Y., Ogawe, M., Nengaki, N. and Zha, M.-R. (2019) Radiosynthesis and in Vivo Evaluation of 11C-Labelled BMS-193885 and Its Dimethyl Analogue as PET Tracers for Neuropeptide Y1 Receptor. EJNMMI Radiopharmacy and Chemistry, 4, 4.
https://doi.org/10.1186/s41181-019-0056-5
|
[70]
|
Winterdahl, M., Audrai, H., Landau, A.M., Smith, D.F., Bonaventur, P., Shoblock, J.R., Carruthers, N., Swanson, D. and Bender, D. (2014) PET Brain Imaging of Neuropeptide Y2 Receptors Using N-11C-Methyl-JNJ-31020028 in Pigs. Journal of Nuclear Medicine, 55, 635-639. https://doi.org/10.2967/jnumed.113.125351
|
[71]
|
Shoblock, J.R., Welty, N., Nepomuceno, D., Lord, B., Aluisio, L., Fraser, I., Motley, S.T., Sutton, S.W., Morton, K., Galici, R., Dvorak, C., Lovenberg, T.W. and Bonaventure, P. (2010) In Vitro and in Vivo Characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethylpiperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a Selective Brain Penetrant Small Molecule Antagonist of the Neuropeptide YY2 Receptor. Psychopharmacology, 208, 265-277.
https://doi.org/10.1007/s00213-009-1726-x
|
[72]
|
Mitapalli, G.K. and Roberts, E. (2014) Ligands of the Neuropeptide YY2 Receptor. Bioorganic & Medicinal Chemistry Letters, 24, 430-441.
https://doi.org/10.1016/j.bmcl.2013.11.061
|
[73]
|
Lunniss, G.E., Barnes, A.A., Barton, N., Biagetti, M., Bianchi, F., Blowers, S.M., Caberlotto, L., Emmons, A., Holmes, I.P., Montanari, D., Norris, R., Walters, J.P. and Watson, S.P. (2009) The Identification and Optimization of Novel and Selective Diamide Neuropeptide Y Y2 Receptor Antagonists. Bioorganic & Medicinal Chemistry Letters, 19, 4022-4025. https://doi.org/10.1016/j.bmcl.2009.06.035
|
[74]
|
Dautzenberg, F.M. and Neysari, S. (2005) Irreversible Binding Kinetics of Neuropeptide Y Ligands to Y2 But Not to Y1 and Y5 Receptors. Pharmacology, 75, 21-24.
https://doi.org/10.1159/000085897
|
[75]
|
Kaiser, A., Müller., P, Zellmann, T., Scheidt, H.A., Thomas,L., Bosse, M., Meier, R., Meiler, J., Huster, D., Beck-Sickinger, A.G. and Schmidt, P. (2015) Unwinding of the C-Terminal Residues of Neuropeptide Y Is Critical for NPY2 Receptor Binding and Activation. Angewandte Chemie International Edition in English, 54, 7446-7449. https://doi.org/10.1002/anie.201411688
|
[76]
|
Tikhonova, I.G., Gigoux, V. and Fourmy (2019) Understanding Peptide Binding in Class A G Protein-Coupled Receptors. Molecular Pharmacology, 119, Article ID: 115915. https://doi.org/10.1124/mol.119.115915
|
[77]
|
Lemus, M.B., Bayliss, J.A., Lockie, S.H., Santos, V.V., Reichenbach, A., Stark, R. and Andrews, Z.B. (2015) A Stereological Analysis of NPY, POMC, Orexin, GFAP Astrocytes and Iba1 Microglia Cell Number and Volume in Diet-Induced Obese Male Mice. Endocrinology, 156, 1701-1713. https://doi.org/10.1210/en.2014-1961
|
[78]
|
Pissarek, M. and Disko, U. (2013) Non-Peptide Ligands in the Characterization of Peptide Receptors at the Interface between Neuroendocrine and Mental Diseases. WJNS, 3, 100-125. https://doi.org/10.4236/wjns.2013.32014
|
[79]
|
Roecker, A.J., Cox, C.D. and Coleman, P.J. (2016) Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. Journal of Medicinal Chemistry, 59, 504-530. https://doi.org/10.1021/acs.jmedchem.5b00832
|
[80]
|
Lin, L., Faraco, J., Li, R., Kadothahi, Rogers, W., Lin, X., Qiu, X., de Jong, P.J., Nishino, S. and Mignot, E. (1999) The Sleep Disorder Canine Narcolepsy Is Caused by Mutation in the Hypocretin (Orexin) Receptor 2 Gene. Cell, 98, 365-376.
https://doi.org/10.1016/S0092-8674(00)81965-0
|
[81]
|
Toner, L.C., Tsambiras, B.M., Catalano, G., Catalano, M.C. and Cooper, D.S. (2000) Central Nervous System Side Effects Associated with Zolpidem Treatment. Clinical Neuropharmacology, 23, 54-58. https://doi.org/10.1097/00002826-200001000-00011
|
[82]
|
Yang, W., Dollear, M. and Muthukrishnan, S.R. (2005) One Rare Side Effect of Zolpidem-Sleepwalking: A Case Report. Archives of Physical Medicine and Rehabilitation, 86, 1265-1266. https://doi.org/10.1016/j.apmr.2004.11.022
|
[83]
|
Farkas, R.H., Unger, E.F. and Temple, R. (2013) Zolpidem and Driving Impairment-Identifying Persons at Risk. The New England Journal of Medicine, 369, 689-691. https://doi.org/10.1056/NEJMp1307972
|
[84]
|
Strother, L.C., Srikiatkhachom, A. and Supronsinchai, W. (2018) Targeted Orexin and Hypothalamic Neuropeptides for Migraine. Neurotherapeutics, 15, 377-390.
https://doi.org/10.1007/s13311-017-0602-3
|
[85]
|
Wang, C., Wang, Q., Ji, B., Pan, Y., Xu, C., Cheng, B., Bai, B. and Chen, J. (2018) The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Frontiers in Molecular Neuroscience, 11, Article 220.
https://doi.org/10.3389/fnmol.2018.00220
|
[86]
|
Mang, G.M., Dürst, T., Bürki, H., Imobersteg, S., Abramowski, D., Schuepbach, E., Hoyer, D., Fendt, M. and Gee, C.E. (2012) The Dual Orexin Receptor Antagonist Alomrexant Induces Sleep and Decreases Orexin-Induced Locomotion by Blocking Orexin 2 Receptors. Sleep, 35, 1625-1635. https://doi.org/10.5665/sleep.2232
|
[87]
|
Bonaventure, P., Shelton, J., Yun, S., Nepomuceno, D., Sutton, S., Aluisio, L., Fraser, I., Lord, B., Shoblock, J., Welty, N., Chaplan, S.R., Agilar, Z., Halter, R., Ndifor, A., Koudriakova, T., Rizzolo, M., Letavic, M., Carruthers, N.I., Lovenberg, T. and Dugovic, C. (2015) Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. Journal of Pharmacology and Experimental Therapeutics, 354, 471-482.
https://doi.org/10.1124/jpet.115.225466
|
[88]
|
Lopez, M.F., Moorman, D.E., Aston-Jones, G. and Becker, H.C. (2016) The Highly Selective Orexin/Hypocretin 1 Receptor Antagonist GSK 1059865 Potently Reduced Ethanol Drinking in Ethanol Dependent Mice. Brain Research, 1636, 74-80.
https://doi.org/10.1016/j.brainres.2016.01.049
|
[89]
|
Lawrence, A.J. (2010) Regulation of Alcohol Seeking by Orexin (Hypocretin) Neurons. Brain Research, 1314, 124-129. https://doi.org/10.1016/j.brainres.2009.07.072
|
[90]
|
Smart, D., Sabido-David, C., Brough, S.J., Jewitt, F., Johns, A., Porter, R.A. and Jerman, J.C. (2001) SB-334867: The First Selective Orexin-1 Receptor Antagonist. British Journal of Pharmacology, 132, 1179-1182.
https://doi.org/10.1038/sj.bjp.0703953
|
[91]
|
Stump, C.A., Cooke, A.J., Bruno, J., Cabalu, T.D., Gotter, A.L., Harrell, C.M., Kuduk, S.D., McDonald, T.P., O’Brien, J., Renger, J.J., Williams, P.D., Winrow, C.J. and Coleman, P.J. (2016) Discovery of Highly Potent and Selective Orexin 1 Receptor Antagonists (1-SORA) Suitable for in Vivo Interrogation of Orexin 1 Receptor Pharmacology. Bioorganic & Medicinal Chemistry Letters, 26, 5809-5814.
https://doi.org/10.1016/j.bmcl.2016.10.019
|
[92]
|
Futamura, A., Nozawa, D., Araki, Y., Tamura, Y., Tokura, S., Kawamoto, H., Tokumaru, Y., Kakihara, S., Aoki, T. and Ohtake, N. (2017) Identification and Synthesis of Highly Selective Orexin 1 Receptor Antagonists Derived from a Dual Orexin Receptor ? Antagonist Based on the Structural Framework of Pyrazoylethylbenzamide. Bioorganic & Medicinal Chemistry, 25, 5203-5215.
https://doi.org/10.1016/j.bmc.2017.07.051
|
[93]
|
Nagase, H., Yamamoto, N., Yata, M., Ohrui, S., Okada, T, Saito, T., Kutsumura, N., Nagumo, Y., Iruknayama-Tomobe, Y., Ishikawa, Y., Ogawa, Y., Hirayama, S., Kuroda, D., Watanabe, Y., Gouda, H. and Yanasigawa, M. (2017) Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies. Journal of Medicinal Chemistry, 60, 1018-1040.
https://doi.org/10.1021/acs.jmedchem.6b01418
|
[94]
|
Yin, J., Babaoglu, K., Brautigam, C.A., Clark, L., Shao, Z., Scheuermann, T.H., Harrell, C.M., Gotter, A.L., Roecker, A.J., Winrow, C.J., Renger, J.J., Coleman, P.J. and Rosenbaum, D.M. (2016) Structure and Ligand Binding Mechanism of the Human OX1 and OX2 Receptors. Nature Structural & Molecular Biology, 23, 293-299.
https://doi.org/10.1038/nsmb.3183
|
[95]
|
Hirose, M., Egashira, S.-I., Goto, Y., Hashihayata, T., Ohtake, N., Iwaasa, H., Hata, M., Fukami, T., Kanatani, A. and Yamada, K. (2003) N-Acyl-6,7-Dimethoxy-1,2,3,4 Tetrahydroisoquinoline. The First Orexin 2 Receptor Selective Nonpeptidic Antagonist. Bioorganic & Medicinal Chemistry Letters, 13, 4497-4499.
https://doi.org/10.1016/j.bmcl.2003.08.038
|
[96]
|
Mensch, J., Oyarzabal, J., Mackie, C. and Augustijins, P.J. (2009) In Vivo, in Vitro and in Silico Methods for Small Molecule Transfer across the BBB. Pharmaceutical Sciences, 98, 4429-4468. https://doi.org/10.1002/jps.21745
|
[97]
|
Fujimoto, T., Tomata, Y., Kunitomo, J., Hirozane, M. and Marui, S. (2011) Discovery of Spiropiperidine-Based Potent and Selective Orexin 2 Receptor Antagonists. Bioorganic & Medicinal Chemistry Letters, 21, 6409-6413.
https://doi.org/10.1016/j.bmcl.2011.08.094
|
[98]
|
Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Fendt, M., Gee, C.E., Jacobson, L.H, Laue, G., Ofner, S., Chaudhari, V., Badiger, S., Pandit, C., Wagner, J. and Hoyer, D. (2013) Identification of a Novel Series of Orexin Receptor Antagonists with a Distict Effect on Sleep Architecture for the Treatment of Insomnia. Journal of Medicinal Chemistry, 56, 7590-7607. https://doi.org/10.1021/jm4007627
|
[99]
|
Wang, C., Wilson, C.M., Moseley, C.K., Carlin, S.M., Hsu, S., Arabasz, G., Schroeder, F.A., Sander, C.Y. and Hooker, J.M. (2013) Evaluation of Potential PET Imaging Probes for the Orexin 2 Receptor. Nuclear Medicine and Biology, 40, 1000-1005.
https://doi.org/10.1016/j.nucmedbio.2013.07.001
|
[100]
|
Malherbe, P., Borroni, E., Gobbi, L., Knust, H., Nettenkoven, M., Pinard, E., Roche, O., Evans, R.M., Wettstein, J.G. and Moreau, J.-L. (2009) Biochemical and Behavioral Characterization of EMPA, a Novel High-Affinity, Selective Antagonist for the OX2 Receptor. British Journal of Pharmacology, 156, 1326-1341.
https://doi.org/10.1111/j.1476-5381.2009.00127.x
|
[101]
|
Schwab, M., Bauer, R. and Zwiener, U. (1997) The Distribution of Normal Brain Water Content in Wistar Rats and Its Increase Due to Ischemia. Brain Research, 749, 82-87. https://doi.org/10.1016/S0006-8993(96)01165-1
|
[102]
|
Kogure, K., Busto, R., Scheinberg, P. and Reinmuth, O.M. (1974) Energy Metabolites and Water Content in Rat Brain during the Early Stage of Development of Cerebral Infarction. Brain, 97, 103-114. https://doi.org/10.1093/brain/97.1.103
|
[103]
|
Lin, W., Paczynski, R.P., Venkatesan, R., He, Y.Y., Powers, W.J., Hsu, C.Y. and Haake, E.M. (1997) Quantitative Regional Brain Water Measurement with Magnetic Resonance Imaging in a Focal Ischemia Model. MRM, 38, 303-310.
https://doi.org/10.1002/mrm.1910380221
|
[104]
|
Lin, W., Venkatesan, R., Gurleyik, K., He, Y.Y., Powers, W.J. and Hsu, C.Y. (2000) An Absolute Measurement of Brain Water Content Using Magnetic Resonance Imagig in Two Cerebral Focal Ischemic Rat Models. Journal of Cerebral Blood Flow & Metabolism, 20, 37-44. https://doi.org/10.1097/00004647-200001000-00007
|
[105]
|
Venkatesan, R., Lin, W., Gurleyik, He, Y.Y., Paczynski, R.P., Powers, W.J. and Hsu, C.Y. (2000) Absolute Measurement of Water Content Using Magnetic Resonance Imaging: Preliminary Findings in an in Vivo Focal Ischemic Rat Model. MRM, 43, 46-150.
https://doi.org/10.1002/(SICI)1522-2594(200001)43:1<146::AID-MRM18>3.0.CO;2-L
|
[106]
|
Skudlarek, J.W., Di Marco, C.N., Babaoglu, K., Roecker, A.J., Bruno, J.G., Pausch, M.A., O’Brien. J.A., Cabalu, T.D., Stevens, J., Brunner, J., Tannenbaum, P.L., Wuelfing, W.P., Garson, S.L., Fox, S.V., Savitz, A.T., Harrell, C.M., Gotter, A.L., Winrow, C.J., Renger, J.J., Kuduk, S.D. and Coleman, P.J. (2017) Investigation of Orexin-2 Selective Receptor Antagonists: Structural Modifications Resulting in Dual Orexin Receptor Antagonists. Bioorganic & Medicinal Chemistry Letters, 27, 1364-1370. https://doi.org/10.1016/j.bmcl.2017.02.012
|
[107]
|
Oi, N., Suzuki, M., Terauchi, T., Tokunaga, M., Nakatani, Y., Yamamoto, N., Fukumura, T., Zhang, M.-R., Suhara, T. and Higuchi, M. (2013) Synthesis and Evaluation of Novel for Positron Emission Tomography Imaging of Orexin 2 Receptors. Journal of Medicinal Chemistry, 56, 6371-6385. https://doi.org/10.1021/jm400772t
|
[108]
|
Gao, M., Wang, M. and Zheng, Q.-H. (2016) Synthesis of [11C]MK-1064 as a New PET Radioligand for Imaging of Orexin-2 Receptors. Bioorganic & Medicinal Chemistry Letters, 26, 3694-3699. https://doi.org/10.1016/j.bmcl.2016.05.083
|
[109]
|
Valdearcos, M., Douglass, J.D., Roblee, M.M., Dorfman, M.D., Stifler, D.R., Bennett, M.L., Gerritse, I., Fasnacht, R., Barres, B.A., Thaler, J.P. and Koliwad, S.K. (2017) Microglial Inflammatory Signaling Orchestrates the Hypothalamic Immune Response to Dietary Excess and Mediates Obesity Susceptibility. Cell Metabolism, 26, 185-197. https://doi.org/10.1016/j.cmet.2017.05.015
|
[110]
|
Dorfman, M.D., Krull, J.E., Douglass, J.D., Fassnacht, R., Lara-Lince, F., Meek, T.H., Shi, X., Damian, V., Nguyen, H.T., Matsen, M.E., Morton, G.J. and Thaler, J.P. (2017) Sex Differences in Microglial CX3CR Signaling Determine Obesity Susceptibility in Mice. Nature Communication, 8, 14556.
https://doi.org/10.1038/ncomms14556
|
[111]
|
Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., Sarnacki, S., Cumano, A., Lauvau, G. and Geissmann, F. (2007) Monitoring of Blood Vessels and Tissue by Population of Monocytes with Patrolling Behavior. Science, 317, 666-670.
https://doi.org/10.1126/science.1142883
|
[112]
|
Dorgham, K., Ghadiri, P., Hermand, P., Rodero, M., Poupel, L., Iga, M., Hartley, O., Gorochov, G., Combadiere, C. and Deterre, P. (2009) An Engineered CX3CR1 Antagonist Endowed with Anti-Inflammatory Activity. Journal of Leukocyte Biology, 86, 903-911. https://doi.org/10.1189/jlb.0308158
|
[113]
|
Dorgham, K., Cerini, F., Gartner, H., Melotti, A., Rossitto-Borlat, I., Gorochov, G. and Hartley, O. (2016) Generating Chemokine Analogs with Enhanced Pharmacological Properties Using Phage Display. Methods in Enzymology, 750, 47-72.
https://doi.org/10.1016/bs.mie.2015.09.014
|
[114]
|
Thal, D.M., Vuckovic, Z., Draper-Joyce, C.J., Liang, Y.-L., Glukhova, A., Christopoulos, A. and Sexton, P.M. (2018) Recent Advances in the Determination of G Protein-Coupled Receptor Structures. Current Opinion Structural Biology, 51, 28-34. https://doi.org/10.1016/j.sbi.2018.03.002
|
[115]
|
Ridderstad Wollberg, A., Ericsson-Dahlstrand, A., Jureu, A., Ekerot, P., Simon, S., Nilsson, M., Wiklund, S.-J., Berg, A.-L., Ferm, M., Sunnemark, D. and Johansson, R. (2014] Pharmacological Inhibition of Chemokine Receptor CX3CR1 Attenuates Disease in a Chronic Relapsing Rat Model of Multiple Sclerosis. PNAS, 111, 5409-5414. https://doi.org/10.1073/pnas.1316510111
|
[116]
|
Seidel, L., Zarzycka, B., Zaidi, S.A. and Katrich, V. (2017) Structural Insight into the Activation of a Class B G-Protein-Coupled Receptor by Peptide Hormones in Live Human Cells. ELife, 6, e27711. https://doi.org/10.7554/eLife.27711
|
[117]
|
Shaham, Y. and de Wit, H. (2016) Lost in Translation: CRF1 Receptor Antagonist and Addiction Treatment. Neuropsychopharmacology, 41, 2795-2797.
https://doi.org/10.1038/npp.2016.94
|
[118]
|
Spierling, R. and Zorilla, E.P. (2017) Don’t Stress about CRF: Assessing the Translational Failures of CRF1 Antagonists. Psychopharmacology, 234, 1467-1481.
https://doi.org/10.1007/s00213-017-4556-2
|
[119]
|
Howerton, A.R., Roland, A.V., Fluharty, J.M., Marshall, A., Chen, A., Daniels, D., Beck, S.G. and Bale, T.L. (2014) Sex Differences in Corticotropin Releasing Factor Receptor-1 Action within the Dorsal Raphe Nucleus in Stress Responsivity. Biological Psychiatry, 75, 873-883. https://doi.org/10.1016/j.biopsych.2013.10.013
|
[120]
|
Lodge, N.J., Li, Y.-W., Chin, F.T., Dischino, D.D., Zoghbi, S.S., Deskus, J.A., Mattson, R.J., Imaizumo, M., Pieschl, R., Molski, T.F., Fujita, M., Dulac, H., Zaczek, R., Bronson, J.J., Maco, J.E., Innis, R.B. and Pike, V.W. (2014) Synthesis and Evaluation of Candidate PET Radioligands for Corticotropin Releasing Factor Type 1 Receptor. Nuclear Medicine and Biology, 41, 524-535.
https://doi.org/10.1016/j.nucmedbio.2014.03.005
|
[121]
|
Stehouwer, J.S., Bourke, C.H., Owens, M.J., Voll, R.J., Kilt, C.D. and Goodman, M.M. (2015) Synthesis, Binding Affinity, Radiolabelling and MicroPET Evaluation of 4-(2-Substituted-4-Substituted)-8-(Dialkylamino)-6-Methyl-1-Substituted-3,4-Dihydro-pyrido-[2,3-b]Pyrazine-2[1H]-ones as Ligands for Brain Corticotropic Releasing Factor Receptor Type 1 (CRF1) Receptors. Bioorganic & Medicinal Chemistry Letters, 25, 5111-5114. https://doi.org/10.1016/j.bmcl.2015.10.010
|
[122]
|
Hartz, R.A., Ahuja, V.T., Zhuo, X., Mattson, R.J., Denhardt, D.J., Deskus, J.A., Vrudhula, V.M., Pan, S., Ditta, J.L., Shu, Y.-Z., Grace, J.E., Lentz, K.A., Lelas, S., Li, Y.-W., Molski, T.F., Krishnananthan, S., Wong, H., Quian-Cutrone, J., Schartmann, R., Denton, R., Lodge, N.J., Zaczek, R., Macor, J.E. and Bronson, J.J. (2009) A Strategy to Minimize Reactive Metabolite Formation: Discovery of (S)-4-(1-Cyclop- rpopyl-2-Methoxyethyl)-6-[6-(Difluoromethoxy)-2,5Dimethylpyridine-3-ylAmino]-5-oxo-4,5-Dihydropyrazine-2-Carbonitrile as a Potent Orally Bioavailable Corticotropin Releasing Factor-1 Receptor Antagonist. Journal of Medicinal Chemistry, 52, 7653-7668. https://doi.org/10.1021/jm900716v
|
[123]
|
Hartz, R.A., Vrudhula, V.M., Ahuja, V.T., Grace, J.E., Lodge, N.J., Bronson, J.J. and Macor, J.E. (2017) Synthesis and Evaluation of Prodrugs of Corticotropin Releasing Factor 1 (CRF) Receptor Antagonist BMS 665053 Leading to Improved Oral Bioavailability. Bioorganic & Medicinal Chemistry Letters, 27, 1360-1363.
https://doi.org/10.1016/j.bmcl.2017.02.015
|
[124]
|
Poel van der, M., Ulas, T., Mizee, M.R., Hsiao, C.-C., Miedema, S.S.M., Schuurman, A.K.G., Heider, B., Tas, S.W., Schultze, J.L., Hamann, J. and Hiutinga, I. (2019) Transcriptional Profiling of Human Microglia Reveals Grey-White Matter Heterogeneity and Multiple Sclerosis-Associated Changes. Nature Communications, 10, Article No. 1139. https://doi.org/10.1038/s41467-019-08976-7
|
[125]
|
Ayata, P., Badimon, A., Strasburger, H.J., Duff, M.K., Montgomery, S.E., Loh, Y.H., Ebert, A., Pimenova, A.A., Ramirez, B.R., Chan, A.T., Sullivan, J.M., Purushothaman, I., Scarpa, J.R., Goate, A.M., Busslinger, M., Shen, L., Losic, B. and Schaefer, A. (2018) Epigenetic Regulation of Brain Region-Specific Microglia Clearance Activity. Nature Neuroscience, 21, 1049-1060. https://doi.org/10.1038/s41593-018-0192-3
|
[126]
|
Sawicki, C.M., Kim, J.K., Weber, M.D., Faw, T.D., McKim, D.B., Madalena, K.M., Lerch, J.K., Basso, D.M., Humeidan, M.L., Godbout, J.P. and Sheridan, J.F. (2019) Microglia Promote Increased Pain Behavior through Enhanced Inflammation in the Spinal Cord during Repeated Social Defeat Stress. Journal of Neuroscience, 39, 1139-1149. https://doi.org/10.1523/JNEUROSCI.2785-18.2018
|
[127]
|
Majer, A., Medina, S.J, Sorensen, D., Martin, M.J., Frost, K.L., Phillipson, C., Manguiat, K. and Booth, S.A. (2019) The Cell Type Resolved Mouse Transcriptome in Neuro-Enriched Brain Tissues from the Hippocampus and Cerebellum during Prion Disease. Scientific Reports, 9, Article No. 1099.
https://doi.org/10.1038/s41598-018-37715-z
|
[128]
|
Franco-Bocanegra, D.K., McAuley, C., Nicoll, J.A.R. and Boche, D. (2019) Molecular Mechanisms of Microglial Motility: Changes in Ageing and Alzheimer’s Disease. Cells, 8, 639. https://doi.org/10.3390/cells8060639
|
[129]
|
Dorand, R.B., Benson, B.L., Huang, L.F., Petrosiute, A. and Huang A.Y. (2019) Insights from Dynamic Neuro-Immune Imaging on Murine Immune Response to CNS Damage. Frontiers in Neuroscience, 13, 737.
https://doi.org/10.3389/fnins.2019.00737
|
[130]
|
Araki, K.Y., Sims, J.R. and Bide, P.G. (2007) Dopamine Receptor mRNA and Dopamine Expression in the Mouse Corpus Striatum and Cerebral Cortex in the Pre- and Postnatal Development. Brain Research, 1156, 31-45.
https://doi.org/10.1016/j.brainres.2007.04.043
|
[131]
|
Ganz, M., Feng, L., Demant-Hansen, H., Beliveau, V., Svarer, C., Knudsen, G.M. and Greve, D.N. (2017) Cerebellar Heterogeneity and Its Impact on PET Data Quantification of 5 HT-Receptor Radioligands. Journal of Cerebral Blood Flow & Metabolism, 37, 3243-3252. https://doi.org/10.1177/0271678X16686092
|